Forgot your password?

Forgot your username?

database > company
RhinoCyte
Biotech Specialty Pharma
201 E. Jefferson, Suite 315
Louisville, KY 40202 USA
phone:(502) 569-1020
fax:(502) 569-1021
Symbol Private
Founded 2005
Employees
www.rhinocyte.com
Research Sector Biotech Specialty Pharma
Summary Description
Stem-cell-based diagnostic tools and therapies for the treatment of degenerative neurological diseases such as Parkinson's and Multiple Sclerosis
Management
Fred Roisen, Founder, President and CEO; Teresa Leezer, VP Business Strategy
Keywords
neurology, stl, ALS, parkinsons, multiple sclerosis, spinal cord injury, christopher reeve, stem cells, neurodegenerative



Comment | Printable Version | Modify profile |
Updated: Nov. 20, 2012

Description
RhinoCyte Inc. is a biotechnology company commercializing autologous adult olfactory-derived stem cell therapies to treat spinal cord injury and neurodegenerative disorders such as Amyotrophic Lateral Sclerosis, Parkinson's disease, and Multiple Sclerosis.
Products / Services

According to a standardized procedure the olfactory tissue would be harvested endoscopically by an ENT physician at the patient's site. The tissue will then be shipped to RhinoCyte's Louisville labor...

view more


Technology / Differentiation
The core technology involves the biopsy, harvesting, isolation, processing, cryo-preservation and engraftment of adult progenitors into the site of injury. RhinoCyte's lead therapeutic candidate is an autologous cellular enhancement therapy which provides a biologically active bridge that promotes recovery of spinal cord injury induced neural damage.
Market / Customers

Spinal cord injury affects more than 250,000 patients in the US alone, with 13,000 new cases annually. According to the National Spinal Cord Injury Statistical Center, annual total costs for spinal co...

view more


Status
The company currently seeks Series B funding to develop and commercialize its lead product for spinal cord injuries, specifically to submit an IND and commence phase I trials in 2010.


2013-06-19-1772